Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706342 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
A Phase 2 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00706342 is a Phase 2 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT00706342, a Phase 2 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
Interventions
- DRUG Fostamatinib Disodium / R935788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706342
The ClinicalTrials.gov registry entry for NCT00706342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fostamatinib Disodium / R935788 is the first listed.
NCT00706342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706342 about?
NCT00706342 is a clinical study titled "Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)". The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
What is the current status of trial NCT00706342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2007-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00706342?
The interventions under investigation include: Fostamatinib Disodium / R935788 (DRUG).
Who is sponsoring clinical trial NCT00706342?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.